More than ever, in vitro testing tools are needed to expand your options in times of distance rules & sanitizing.
We would like to share with you an interesting study with our Tewitro® TW 24 made by Johnson & Johnson France.
The exciting aim of the study is to contribute to the mechanistic understanding of the clinically observed Cutaneous adverse drug reactions
(CADR) associated with oncology therapy.
The article was published in BMC Cancer 21, 5
(2021) by Nicolas Joly-Tonetti
, Thomas Ondet
, Mario Monshouwer
& Georgios N. Stamatas
of the French Johnson & Johnson Research Group.
The in vitro results suggest a specific mode of action of Epidermal Growth Factor Receptor inhibitors (EGFRi) targeting carcinomas by directly affecting keratinocyte growth and barrier function.